Remarkable advancements have been made in the field of migraine pathophysiology and
pharmacotherapy over the past decade. Understanding the molecular mechanism of …

Migraine is a highly prevalent, complex neurological disorder. The burden of disease and
the direct/indirect annual costs are enormous. Thus far, treatment options have been …

Background and purpose Based on their pharmacological target, two classes of calcitonin‐
gene‐related peptide (CGRP) monoclonal antibodies (mAbs) have been identified …

With the approval of calcitonin gene-related peptide (CGRP) and CGRP receptor
monoclonal antibodies by the Federal Drug Administration, a new era in the treatment of …

The neuropeptide calcitonin gene-related peptide (CGRP) is an essential
pathophysiological treatment for migraines. A unique class of medications called CGRP …

Recently, monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide
(CGRP)(Eptinezumab, Fremanezumab, and Galcanezumab) or its receptor (Erenumab) …

Calcitonin gene-related peptide (CGRP), a potent vasodilator and pain-signaling
neuropeptide, is a validated therapeutic target for migraine and cluster headache. Four anti …

CGRP is an extensively studied neuropeptide that has been implicated in the
pathophysiology of migraine. While a number of small molecule antagonists against the …

In the past few years, a number of new migraine treatments have emerged, including
monoclonal antibodies against calcitonin gene-related peptide (CGRP) and the CGRP …

Purpose of Review CGRP is a key neuropeptide in migraine pathophysiology. The blockade
of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the …